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Abstract 
Objectives: Bordetella pertussis is the etiological agent of whooping cough, a bacterial infection of especially chil-
dren, which may be fatal without treatment. In frame of studies to investigate putative effects of vaccination on host–
pathogen interaction and clonal distribution of strains, in addition to Corynebacterium diphtheriae and Clostridium 
tetani toxoid vaccines, also whole-cell and acellular pertussis vaccines were analyzed by mass spectrometry.
Data description: LC–MS/MS spectra were generated and analyzed using B. pertussis genome data and proteins 
present in whole-cell and acellular pertussis vaccines were identified. Subcellular localization of proteins and presence 
of signal peptides was determined bioinformatically.
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Objective
Bordetella pertussis is the etiological agent of whooping 
cough, a bacterial infection of especially children, which 
may be fatal without treatment. In 2008 about 16 million 
cases of whooping cough—also designated as pertussis—
resulting in almost 200,000 pediatric deaths were esti-
mated by the World Health Organization, while for 2015 
more than 60,000 deaths of infants were assumed [1–3]. 
These numbers of worldwide cases illustrate that pertus-
sis is a continuing threat to children’s health and vacci-
nation is important to prevent this infection. In frame 
of studies to investigate putative effects of vaccination 
on host–pathogen interaction and clonal distribution of 
strains, in addition to Corynebacterium diphtheriae [4] 
and Clostridium tetani [5] toxoid vaccines, also pertus-
sis vaccines were analyzed by mass spectrometry (MS). 
In order to identify putative immunogenic proteins and 
to provide data to understand the influence of vaccina-
tion on the distribution of B. pertussis strains, two dif-
ferent types of vaccines were analyzed in respect to their 
protein content: a whole-cellular and an acellular pertus-
sis vaccine. Whole-cell vaccines are suspensions of killed 
B. pertussis cells, while the acellular pertussis vaccines, 
which were developed to prevent unwanted local reac-
tions of the whole-cell vaccine, contain only a limited 
number of purified components (for overview of different 
vaccine formulations see [3]. An influence of vaccination 
strategy used and components included in the vaccine 
on evolution of B. pertussis strains in human populations 
was already discussed [6, 7], based on an observed effect 
of vaccination on the distribution of different alleles in 
B. pertussis. For example, the pertactin-encoding prn1 
allele was dominating in the pre-vaccine era, while after 
introduction of the whole-cellular vaccine produced with 
a prn1-carrying strain, B. pertussis isolates harboring the 
prn2 allele increased [8]. Also a change in the fimbrial 
serotype of B. pertussis strains was observed from sero-
type Fim2 predominantly found in unvaccinated popula-
tions to serotype Fim3 and serotype Fim2,3 in vaccinated 
populations [9]. Since proteome analyses of B. pertussis 
and corresponding vaccines are scarce [10], the proteom-
ics data presented in this data note may be helpful for 
further evolutionary studies.
Data description
The data represent proteomic analyses of commercially 
vaccines, an acellular and a whole cellular pertussis vac-
cine. Raw data files (.raw), MS/MS spectra files (.msf ), 
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peptide sequence assignment files of MS/MS scans (pep.
xml) as well as a list of identified proteins (.xlsx) were 
deposited to the ProteomeXchange Consortium (http://
prote omece ntral .prote omexc hange .org) via the PRIDE 
partner repository [11] and are available with identifier 
PXD013804 (Table  1). The data set provided includes a 
table with identified proteins in the analyzed vaccines, 
their molecular function and cellular localization as well 
as a PDF file containing three images depicting these 
results, a list with vaccines used in this study and a table 
with identified proteins related to pathogenicity (Table 1).
Methodology
Protein sample preparation
Bordetella pertussis vaccines are typically administered 
in combination with diphtheria and tetanus toxoid vac-
cines as DTP3 vaccines. In this study, we analyzed one 
acellular and one whole cellular commercially available 
pertussis vaccine (for details, see Data set 1). The sample 
preparation of the vaccines for mass spectrometry analy-
sis was carried out as described recently [4, 5]. In short, 
the proteins were transferred to 10 kDa membrane filters 
and processed using a modified protocol for Filter Aided 
Sample Preparation (FASP) [12, 13]. After filter-based 
tryptic digest and elution, the peptides were desalted and 
concentrated using C18 stage tips. Prior to LC–MS/MS 
(liquid chromatography tandem–mass spectrometry), 
peptides were vacuum dried and solved in 0.1% trifluoro-
acetic acid (TFA) [14].
Mass spectrometry and data analysis
Mass spectrometric analyses were carried out as 
described before [4, 5, 13, 14] using a combination of 
a nanoflow Ultimate 3000 HPLC (Dionex, Sunnyvale, 
CA, USA) and an Orbitrap Fusion mass spectrometer 
(Thermo Fisher Scientific, Waltham, MA, USA). Result-
ing raw data files were analyzed using the C. diphtheriae 
ATCC 700971/NCTC 13129/Biotype gravis database 
(Proteome Id: UP000002198), the Clostridium tetani E88 
database, (Proteome Id: UP000001412) and the Borde-
tella pertussis (strain Tohama I/ATCC BAA-589/NCTC 
13251) database (Proteome Id.: UP000002676) using 
the Proteome Discoverer 1.4 program package (Thermo 
Fisher Scientific, Bremen, Germany). Identification of 
product ions was carried out as described recently [4, 
5]: theoretical peptide masses for trypsin digestion were 
generated allowing two missed cleavages and the follow-
ing settings were used for analysis: (i) carbamidomethyl 
modification of cysteine residues fixed, (ii) oxidation of 
methionine dynamic, (iii) mass tolerance 10 ppm for sur-
vey scans, (iv) 0.6 Da for fragment mass measurements, 
(v) protein identification threshold 1% false discovery 
rate (FDR).
In total 1855 unique proteins were identified by mass 
spectrometry analyses with 1850 distinct proteins identi-
fied in the whole cellular vaccine and 25 unique identified 
in the acellular vaccine.
Limitations
The data presented here were obtained in frame of a pro-
ject focusing on diphtheria and tetanus toxoid vaccines. 
Since these vaccines are administered in different com-
binations, only part of the samples contained B. pertussis 
proteins and the number of pertussis vaccines was lim-
ited to three.
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Table 1 Overview of data files/data sets
Label Name of data file/data set File types (file extension) Data repository and identifier (DOI 
or accession number)
Data set 1 [15] Bordetella pertussis vaccine project RAW data file (.raw), MS/MS spectra files 
(.msf ), MS Excel file (.xlsx), peptide 
sequence assignment files (pep.xml)
http://ident ifier s.org/pride .proje ct:PXD01 
3804
Data set 2 [16] Results table MS Excel file (.xlsx) https ://doi.org/10.6084/m9.figsh are.81081 65
Data set 3 [17] Images of Bordetella pertussis vaccine 
analysis
PDF (.pdf ) https ://doi.org/10.6084/m9.figsh are.81082 10
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